Roche, Spark Therapeutics Extend Tender Offer Period After FCA Requests More Information
June 10 2019 - 1:52AM
Dow Jones News
By Cristina Roca
Roche Holding AG (RO.EB) has extended the offering period for
its planned acquisition of Philadelphia-based biotechnology company
Spark Therapeutics Inc. (ONCE), it said Monday.
The offering period has been extended to July 31, from a
previous deadline of June 14, as a result of a request for
additional information from the U.S. Federal Trade Commission, or
FCA, under the Hart-Scott-Rodino Antitrust Improvements Act. The
FCA is reviewing the acquisition of Spark by the Swiss
pharmaceuticals company.
The offer period has been extended multiple times since Roche
announced in February that it would buy Spark.
Roche said the U.K. Competition and Markets Authority has opened
an investigation in order to obtain further information in relation
to Roche's proposed acquisition of Spark.
Write to Cristina Roca at cristina.roca@dowjones.com;
@_cristinaroca
(END) Dow Jones Newswires
June 10, 2019 01:37 ET (05:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
